Login to Your Account



Deals And M&A NEWS

Newly formed Seelos Therapeutics Inc. is "pretty well positioned to raise money," Ligand Pharmaceuticals Inc. President Matthew Foehr told BioWorld Today, and that's what Seelos needs to do in the four-piece licensing deal with San Diego-based Ligand.

The Medicines Co. and Roche AG unit Hoffmann-Laroche Inc. are joining the effort launched by BARDA to develop products to combat the emerging threat of multidrug-resistant bacterial infections, superbugs.

CEO Stephen Hurly told BioWorld Today that Viventia Bio Inc.'s bid to lift ADCs "to the next level" in oncology powered a merger deal with Eleven Biotherapeutics Inc., a peer in protein engineering.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: